ID   EPHB3_HUMAN             Reviewed;         998 AA.
AC   P54753; Q7Z740;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   27-SEP-2005, sequence version 2.
DT   12-OCT-2022, entry version 207.
DE   RecName: Full=Ephrin type-B receptor 3;
DE            EC=2.7.10.1;
DE   AltName: Full=EPH-like tyrosine kinase 2;
DE            Short=EPH-like kinase 2;
DE   AltName: Full=Embryonic kinase 2;
DE            Short=EK2;
DE            Short=hEK2;
DE   AltName: Full=Tyrosine-protein kinase TYRO6;
DE   Flags: Precursor;
GN   Name=EPHB3; Synonyms=ETK2, HEK2, TYRO6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], IDENTIFICATION OF EFNB1 AND EFNB2 AS LIGANDS,
RP   AND AUTOPHOSPHORYLATION.
RC   TISSUE=Embryo;
RX   PubMed=8397371;
RA   Boehme B., Holtrich U., Wolf G., Luzius H., Grzeschik K.-H., Strebhardt K.,
RA   Ruebsamen-Waigmann H.;
RT   "PCR mediated detection of a new human receptor-tyrosine-kinase, HEK 2.";
RL   Oncogene 8:2857-2862(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NOMENCLATURE.
RX   PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0;
RG   Eph nomenclature committee;
RT   "Unified nomenclature for Eph family receptors and their ligands, the
RT   ephrins.";
RL   Cell 90:403-404(1997).
RN   [4]
RP   PHOSPHORYLATION AT TYR-614, AND MUTAGENESIS OF TYR-614 AND LYS-665.
RX   PubMed=9674711; DOI=10.1038/sj.onc.1201907;
RA   Hock B., Boehme B., Karn T., Feller S., Ruebsamen-Waigmann H.,
RA   Strebhardt K.;
RT   "Tyrosine-614, the major autophosphorylation site of the receptor tyrosine
RT   kinase HEK2, functions as multi-docking site for SH2-domain mediated
RT   interactions.";
RL   Oncogene 17:255-260(1998).
RN   [5]
RP   AUTOPHOSPHORYLATION, FUNCTION IN CELL ADHESION, FUNCTION IN CELL MIGRATION,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=15536074; DOI=10.1074/jbc.m411383200;
RA   Miao H., Strebhardt K., Pasquale E.B., Shen T.L., Guan J.L., Wang B.;
RT   "Inhibition of integrin-mediated cell adhesion but not directional cell
RT   migration requires catalytic activity of EphB3 receptor tyrosine kinase.
RT   Role of Rho family small GTPases.";
RL   J. Biol. Chem. 280:923-932(2005).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [7]
RP   UBIQUITINATION BY RNF186.
RX   PubMed=33280498; DOI=10.1080/15548627.2020.1851496;
RA   Zhang H., Cui Z., Cheng D., Du Y., Guo X., Gao R., Chen J., Sun W., He R.,
RA   Ma X., Peng Q., Martin B.N., Yan W., Rong Y., Wang C.;
RT   "RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic
RT   epithelial cells for the maintenance of intestinal homeostasis.";
RL   Autophagy 17:3030-3047(2021).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 39-211, AND DISULFIDE BOND.
RG   Structural genomics consortium (SGC);
RT   "Ligand binding domain of human EPHB3.";
RL   Submitted (JAN-2011) to the PDB data bank.
RN   [9]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-168; CYS-440; VAL-579; LEU-601 AND
RP   TRP-724.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously
CC       transmembrane ephrin-B family ligands residing on adjacent cells,
CC       leading to contact-dependent bidirectional signaling into neighboring
CC       cells. The signaling pathway downstream of the receptor is referred to
CC       as forward signaling while the signaling pathway downstream of the
CC       ephrin ligand is referred to as reverse signaling. Generally has an
CC       overlapping and redundant function with EPHB2. Like EPHB2, functions in
CC       axon guidance during development regulating for instance the neurons
CC       forming the corpus callosum and the anterior commissure, 2 major
CC       interhemispheric connections between the temporal lobes of the cerebral
CC       cortex. In addition to its role in axon guidance also plays an
CC       important redundant role with other ephrin-B receptors in development
CC       and maturation of dendritic spines and the formation of excitatory
CC       synapses. Controls other aspects of development through regulation of
CC       cell migration and positioning. This includes angiogenesis, palate
CC       development and thymic epithelium development for instance. Forward and
CC       reverse signaling through the EFNB2/EPHB3 complex also regulate
CC       migration and adhesion of cells that tubularize the urethra and septate
CC       the cloaca. Finally, plays an important role in intestinal epithelium
CC       differentiation segregating progenitor from differentiated cells in the
CC       crypt. {ECO:0000269|PubMed:15536074}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer
CC       is composed of an ephrin dimer and a receptor dimer. Oligomerization is
CC       probably required to induce biological responses (By similarity).
CC       {ECO:0000250}.
CC   -!- INTERACTION:
CC       P54753; P37235: HPCAL1; NbExp=3; IntAct=EBI-968308, EBI-749311;
CC       P54753; O75031: HSF2BP; NbExp=3; IntAct=EBI-968308, EBI-7116203;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15536074};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:15536074}. Cell
CC       projection, dendrite {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- PTM: Phosphorylated. Autophosphorylates upon ligand-binding.
CC       Autophosphorylation on Tyr-614 is required for interaction with SH2
CC       domain-containing proteins. {ECO:0000269|PubMed:9674711}.
CC   -!- PTM: Ubiquitinated by RNF186, mainly through 'Lys-48' and 'Lys-63'-
CC       linked polyubiquitin chains. {ECO:0000269|PubMed:33280498}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X75208; CAA53021.1; -; mRNA.
DR   EMBL; BC052968; AAH52968.1; -; mRNA.
DR   CCDS; CCDS3268.1; -.
DR   PIR; S37627; S37627.
DR   RefSeq; NP_004434.2; NM_004443.3.
DR   PDB; 3P1I; X-ray; 2.10 A; A/B/C=39-211.
DR   PDB; 3ZFY; X-ray; 2.20 A; A/B=616-910.
DR   PDB; 5L6O; X-ray; 1.88 A; A=616-910.
DR   PDB; 5L6P; X-ray; 2.26 A; A=616-910.
DR   PDBsum; 3P1I; -.
DR   PDBsum; 3ZFY; -.
DR   PDBsum; 5L6O; -.
DR   PDBsum; 5L6P; -.
DR   AlphaFoldDB; P54753; -.
DR   SMR; P54753; -.
DR   BioGRID; 108363; 24.
DR   IntAct; P54753; 22.
DR   MINT; P54753; -.
DR   STRING; 9606.ENSP00000332118; -.
DR   BindingDB; P54753; -.
DR   ChEMBL; CHEMBL4901; -.
DR   DrugCentral; P54753; -.
DR   GuidetoPHARMACOLOGY; 1832; -.
DR   GlyConnect; 1213; 10 N-Linked glycans (2 sites).
DR   GlyGen; P54753; 3 sites, 1 Asn glycan (1 site), 9 N-linked glycans (2 sites), 1 O-linked glycan (1 site).
DR   iPTMnet; P54753; -.
DR   PhosphoSitePlus; P54753; -.
DR   BioMuta; EPHB3; -.
DR   DMDM; 76803655; -.
DR   EPD; P54753; -.
DR   jPOST; P54753; -.
DR   MassIVE; P54753; -.
DR   MaxQB; P54753; -.
DR   PaxDb; P54753; -.
DR   PeptideAtlas; P54753; -.
DR   PRIDE; P54753; -.
DR   ProteomicsDB; 56711; -.
DR   Antibodypedia; 2107; 618 antibodies from 36 providers.
DR   DNASU; 2049; -.
DR   Ensembl; ENST00000330394.3; ENSP00000332118.2; ENSG00000182580.3.
DR   GeneID; 2049; -.
DR   KEGG; hsa:2049; -.
DR   MANE-Select; ENST00000330394.3; ENSP00000332118.2; NM_004443.4; NP_004434.2.
DR   UCSC; uc003foz.4; human.
DR   CTD; 2049; -.
DR   DisGeNET; 2049; -.
DR   GeneCards; EPHB3; -.
DR   HGNC; HGNC:3394; EPHB3.
DR   HPA; ENSG00000182580; Tissue enhanced (skin).
DR   MIM; 601839; gene.
DR   neXtProt; NX_P54753; -.
DR   OpenTargets; ENSG00000182580; -.
DR   PharmGKB; PA27826; -.
DR   VEuPathDB; HostDB:ENSG00000182580; -.
DR   eggNOG; KOG0196; Eukaryota.
DR   GeneTree; ENSGT00940000158024; -.
DR   HOGENOM; CLU_000288_141_0_1; -.
DR   InParanoid; P54753; -.
DR   OMA; TSACSRC; -.
DR   OrthoDB; 933071at2759; -.
DR   PhylomeDB; P54753; -.
DR   TreeFam; TF315608; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P54753; -.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928664; Ephrin signaling.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   SignaLink; P54753; -.
DR   SIGNOR; P54753; -.
DR   BioGRID-ORCS; 2049; 14 hits in 1112 CRISPR screens.
DR   ChiTaRS; EPHB3; human.
DR   EvolutionaryTrace; P54753; -.
DR   GeneWiki; EPHB3; -.
DR   GenomeRNAi; 2049; -.
DR   Pharos; P54753; Tchem.
DR   PRO; PR:P54753; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P54753; protein.
DR   Bgee; ENSG00000182580; Expressed in pancreatic ductal cell and 182 other tissues.
DR   Genevisible; P54753; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008046; F:axon guidance receptor activity; IEA:Ensembl.
DR   GO; GO:0005003; F:ephrin receptor activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0005005; F:transmembrane-ephrin receptor activity; IBA:GO_Central.
DR   GO; GO:0001525; P:angiogenesis; ISS:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; ISS:UniProtKB.
DR   GO; GO:0007413; P:axonal fasciculation; ISS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IDA:UniProtKB.
DR   GO; GO:0021952; P:central nervous system projection neuron axonogenesis; IEA:Ensembl.
DR   GO; GO:0022038; P:corpus callosum development; ISS:UniProtKB.
DR   GO; GO:0060996; P:dendritic spine development; ISS:UniProtKB.
DR   GO; GO:0060997; P:dendritic spine morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048546; P:digestive tract morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0050770; P:regulation of axonogenesis; ISS:UniProtKB.
DR   GO; GO:0022407; P:regulation of cell-cell adhesion; IDA:UniProtKB.
DR   GO; GO:0043087; P:regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0031290; P:retinal ganglion cell axon guidance; IEA:Ensembl.
DR   GO; GO:0060021; P:roof of mouth development; ISS:UniProtKB.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IDA:UniProtKB.
DR   GO; GO:0048538; P:thymus development; ISS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0001655; P:urogenital system development; ISS:UniProtKB.
DR   CDD; cd10478; EphR_LBD_B3; 1.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 1.10.150.50; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR034245; EphB3_rcpt_lig-bd.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR008979; Galactose-bd-like_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF07699; Ephrin_rec_like; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Angiogenesis; ATP-binding; Cell membrane; Cell projection;
KW   Developmental protein; Disulfide bond; Glycoprotein; Kinase; Membrane;
KW   Neurogenesis; Nucleotide-binding; Phosphoprotein; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL          1..33
FT                   /evidence="ECO:0000255"
FT   CHAIN           34..998
FT                   /note="Ephrin type-B receptor 3"
FT                   /id="PRO_0000016831"
FT   TOPO_DOM        34..559
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        560..580
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        581..998
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          39..217
FT                   /note="Eph LBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00883"
FT   DOMAIN          339..451
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          452..545
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          633..896
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          925..989
FT                   /note="SAM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00184"
FT   MOTIF           996..998
FT                   /note="PDZ-binding"
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        758
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         639..647
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         665
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         614
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:9674711"
FT   CARBOHYD        351
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        445
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        81..199
FT                   /evidence="ECO:0000269|Ref.8"
FT   VARIANT         168
FT                   /note="R -> L (in a lung small cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042176"
FT   VARIANT         440
FT                   /note="R -> C (in dbSNP:rs56029711)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042177"
FT   VARIANT         579
FT                   /note="I -> V (in dbSNP:rs56103851)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042178"
FT   VARIANT         601
FT                   /note="I -> L (in dbSNP:rs56129875)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042179"
FT   VARIANT         724
FT                   /note="R -> W (in a lung neuroendocrine carcinoma sample;
FT                   somatic mutation; dbSNP:rs371378866)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042180"
FT   MUTAGEN         614
FT                   /note="Y->F: Partial loss of phosphorylation and loss of
FT                   interaction with SH2-containing proteins."
FT                   /evidence="ECO:0000269|PubMed:9674711"
FT   MUTAGEN         665
FT                   /note="K->R: Kinase-dead. Loss of autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:9674711"
FT   CONFLICT        367
FT                   /note="G -> V (in Ref. 1; CAA53021)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        406..408
FT                   /note="TER -> SEP (in Ref. 1; CAA53021)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        412
FT                   /note="I -> T (in Ref. 1; CAA53021)"
FT                   /evidence="ECO:0000305"
FT   STRAND          39..44
FT                   /evidence="ECO:0007829|PDB:3P1I"
FT   HELIX           45..47
FT                   /evidence="ECO:0007829|PDB:3P1I"
FT   STRAND          55..58
FT                   /evidence="ECO:0007829|PDB:3P1I"
FT   STRAND          63..68
FT                   /evidence="ECO:0007829|PDB:3P1I"
FT   STRAND          74..80
FT                   /evidence="ECO:0007829|PDB:3P1I"
FT   STRAND          85..87
FT                   /evidence="ECO:0007829|PDB:3P1I"
FT   STRAND          90..93
FT                   /evidence="ECO:0007829|PDB:3P1I"
FT   STRAND          103..114
FT                   /evidence="ECO:0007829|PDB:3P1I"
FT   HELIX           116..118
FT                   /evidence="ECO:0007829|PDB:3P1I"
FT   STRAND          130..139
FT                   /evidence="ECO:0007829|PDB:3P1I"
FT   STRAND          155..160
FT                   /evidence="ECO:0007829|PDB:3P1I"
FT   STRAND          175..181
FT                   /evidence="ECO:0007829|PDB:3P1I"
FT   STRAND          186..198
FT                   /evidence="ECO:0007829|PDB:3P1I"
FT   STRAND          200..210
FT                   /evidence="ECO:0007829|PDB:3P1I"
FT   STRAND          633..640
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   STRAND          646..652
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   STRAND          655..657
FT                   /evidence="ECO:0007829|PDB:5L6P"
FT   STRAND          660..666
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   HELIX           673..687
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   STRAND          697..701
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   STRAND          703..706
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   STRAND          708..712
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   HELIX           719..725
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   TURN            726..728
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   HELIX           732..751
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   HELIX           761..763
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   STRAND          764..766
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   STRAND          772..774
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   STRAND          791..793
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   STRAND          796..798
FT                   /evidence="ECO:0007829|PDB:5L6P"
FT   HELIX           802..804
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   HELIX           807..812
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   HELIX           817..832
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   TURN            838..841
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   HELIX           844..852
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   HELIX           865..874
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   TURN            879..881
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   HELIX           885..897
FT                   /evidence="ECO:0007829|PDB:5L6O"
FT   HELIX           899..902
FT                   /evidence="ECO:0007829|PDB:5L6O"
SQ   SEQUENCE   998 AA;  110330 MW;  9B65A4EF58B27407 CRC64;
     MARARPPPPP SPPPGLLPLL PPLLLLPLLL LPAGCRALEE TLMDTKWVTS ELAWTSHPES
     GWEEVSGYDE AMNPIRTYQV CNVRESSQNN WLRTGFIWRR DVQRVYVELK FTVRDCNSIP
     NIPGSCKETF NLFYYEADSD VASASSPFWM ENPYVKVDTI APDESFSRLD AGRVNTKVRS
     FGPLSKAGFY LAFQDQGACM SLISVRAFYK KCASTTAGFA LFPETLTGAE PTSLVIAPGT
     CIPNAVEVSV PLKLYCNGDG EWMVPVGACT CATGHEPAAK ESQCRPCPPG SYKAKQGEGP
     CLPCPPNSRT TSPAASICTC HNNFYRADSD SADSACTTVP SPPRGVISNV NETSLILEWS
     EPRDLGGRDD LLYNVICKKC HGAGGASACS RCDDNVEFVP RQLGLTERRV HISHLLAHTR
     YTFEVQAVNG VSGKSPLPPR YAAVNITTNQ AAPSEVPTLR LHSSSGSSLT LSWAPPERPN
     GVILDYEMKY FEKSEGIAST VTSQMNSVQL DGLRPDARYV VQVRARTVAG YGQYSRPAEF
     ETTSERGSGA QQLQEQLPLI VGSATAGLVF VVAVVVIAIV CLRKQRHGSD SEYTEKLQQY
     IAPGMKVYID PFTYEDPNEA VREFAKEIDV SCVKIEEVIG AGEFGEVCRG RLKQPGRREV
     FVAIKTLKVG YTERQRRDFL SEASIMGQFD HPNIIRLEGV VTKSRPVMIL TEFMENCALD
     SFLRLNDGQF TVIQLVGMLR GIAAGMKYLS EMNYVHRDLA ARNILVNSNL VCKVSDFGLS
     RFLEDDPSDP TYTSSLGGKI PIRWTAPEAI AYRKFTSASD VWSYGIVMWE VMSYGERPYW
     DMSNQDVINA VEQDYRLPPP MDCPTALHQL MLDCWVRDRN LRPKFSQIVN TLDKLIRNAA
     SLKVIASAQS GMSQPLLDRT VPDYTTFTTV GDWLDAIKMG RYKESFVSAG FASFDLVAQM
     TAEDLLRIGV TLAGHQKKIL SSIQDMRLQM NQTLPVQV
//
